A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer (Genentech Inc.DST4964g).

Trial Profile

A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer (Genentech Inc.DST4964g).

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Vandortuzumab vedotin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Genentech
  • Most Recent Events

    • 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development: 2017 Annual Meeting of the American College of Clinical Pharmacology.
    • 05 Sep 2016 Status changed from recruiting to completed.
    • 13 Oct 2014 Planned number of patients changed from 67 to 87 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top